These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 35394865)
21. Stabilization of estrogen receptor α by USP37 contributes to the progression of breast cancer. Cao J; Wang X; Wang S; Chen Z; Tang J Cancer Sci; 2023 May; 114(5):2041-2052. PubMed ID: 36221793 [TBL] [Abstract][Full Text] [Related]
22. The helix 1-3 loop in the glucocorticoid receptor LBD is a regulatory element for FKBP cochaperones. Cluning C; Ward BK; Rea SL; Arulpragasam A; Fuller PJ; Ratajczak T Mol Endocrinol; 2013 Jul; 27(7):1020-35. PubMed ID: 23686112 [TBL] [Abstract][Full Text] [Related]
23. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. Wochnik GM; Rüegg J; Abel GA; Schmidt U; Holsboer F; Rein T J Biol Chem; 2005 Feb; 280(6):4609-16. PubMed ID: 15591061 [TBL] [Abstract][Full Text] [Related]
24. USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α. Cao J; Wu D; Wu G; Wang Y; Ren T; Wang Y; Lv Y; Sun W; Wang J; Qian C; He L; Yang K; Li H; Gu H Cell Death Dis; 2021 Jun; 12(6):619. PubMed ID: 34131114 [TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells. Lo R; Burgoon L; Macpherson L; Ahmed S; Matthews J Biochim Biophys Acta; 2010; 1799(5-6):469-79. PubMed ID: 20079471 [TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer. Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638 [TBL] [Abstract][Full Text] [Related]
27. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression. Zhang B; Zhang X; Tang B; Zheng P; Zhang Y Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650 [TBL] [Abstract][Full Text] [Related]
28. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448 [No Abstract] [Full Text] [Related]
29. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage. Yu S; Gong X; Ma Z; Zhang M; Huang L; Zhang J; Zhao S; Zhu T; Yu Z; Chen L Cell Oncol (Dordr); 2020 Feb; 43(1):65-80. PubMed ID: 31701491 [TBL] [Abstract][Full Text] [Related]
30. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079 [TBL] [Abstract][Full Text] [Related]
31. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy. Fukui F; Hayashi SI; Yamaguchi Y J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282 [TBL] [Abstract][Full Text] [Related]
32. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer. Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890 [TBL] [Abstract][Full Text] [Related]
33. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285 [TBL] [Abstract][Full Text] [Related]
34. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer. Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258 [TBL] [Abstract][Full Text] [Related]
35. Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells. Zhang X; Mukerji R; Samadi AK; Cohen MS BMC Complement Altern Med; 2011 Oct; 11():84. PubMed ID: 21978374 [TBL] [Abstract][Full Text] [Related]
36. NFAT activation by FKBP52 promotes cancer cell proliferation by suppressing p53. Hanaki S; Habara M; Tomiyasu H; Sato Y; Miki Y; Masaki T; Shibutani S; Shimada M Life Sci Alliance; 2024 Aug; 7(8):. PubMed ID: 38803221 [TBL] [Abstract][Full Text] [Related]
37. miRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer. Kim YS; Park SJ; Lee YS; Kong HK; Park JH Oncotarget; 2016 Jul; 7(27):42261-42273. PubMed ID: 27304060 [TBL] [Abstract][Full Text] [Related]
38. Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer. Andruska N; Zheng X; Yang X; Helferich WG; Shapiro DJ Oncogene; 2015 Jul; 34(29):3760-9. PubMed ID: 25263449 [TBL] [Abstract][Full Text] [Related]
39. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences. Giulianelli S; Riggio M; Guillardoy T; Pérez Piñero C; Gorostiaga MA; Sequeira G; Pataccini G; Abascal MF; Toledo MF; Jacobsen BM; Guerreiro AC; Barros A; Novaro V; Monteiro FL; Amado F; Gass H; Abba M; Helguero LA; Lanari C Int J Cancer; 2019 Oct; 145(7):1874-1888. PubMed ID: 30843188 [TBL] [Abstract][Full Text] [Related]
40. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Periyasamy S; Hinds T; Shemshedini L; Shou W; Sanchez ER Oncogene; 2010 Mar; 29(11):1691-701. PubMed ID: 20023700 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]